title: Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept.
abstract: Psoriasis affects 0.12% to 0.71% of all children. Erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5% of cases. Tumor necrosis factor-alpha blockers (TNF-α) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. Etanercept is a TNFα receptor fusion protein, approved by the FDA for treating juvenile rheumatoid arthritis. We present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. Patient responded excellently to etanercept, with no adverse side effects.
authors: Universidade Federal da Bahia, Salvador, BA, Brasil. naiarafraga@yahoo.com.br
authors: Naiara Abreu de Azevedo
authors: NA
authors: Fraga
authors: Maria de Fátima
authors: Mde F
authors: Paim
authors: Ivonise
authors: I
authors: Follador
authors: Andréia Nogueira
authors: AN
authors: Ramos
authors: Vitória Regina Pedreira de Almeida
authors: VR
authors: Rêgo
mesh_terms: D002648:Child; D003873:Dermatitis, Exfoliative / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate